

Versio 5.1	n Revision Date: 30.09.2023		S Number: 33-00027		ue: 04.04.2023 sue: 16.02.2015
0					
Sectio	on 1: Identification				
P	roduct name	:	Doravirine / Lami Formulation	vudine / Tenofo	vir Disoproxil Fumarate Bilayer
М	anufacturer or supplier's d	etai	ls		
C	ompany	:	MSD		
A	ddress	:	33 Whakatiki Stre Upper Hutt - New	•	908
Те	elephone	:	0800 800 543		
E	mergency telephone number	:	0800 764 766 (08 CHEMCALL)	300 POISON)	0800 243 622 (0800
E	-mail address	:	EHSDATASTEW	ARD@msd.con	n
R	ecommended use of the ch	nem	ical and restrictio	ons on use	
	ecommended use estrictions on use	:	Pharmaceutical Not applicable		

Section 2: Hazard identification

GHS Classification Serious eye damage/eye irri- tation	:	Category 2
Reproductive toxicity	:	Category 2
Specific target organ toxicity - repeated exposure (Oral)	:	Category 2 (Blood, Bone, Kidney)
GHS label elements Hazard pictograms	:	
Signal word	:	Warning
Hazard statements	:	H319 Causes serious eye irritation. H361d Suspected of damaging the unborn child. H373 May cause damage to organs (Blood, Bone, Kidney) through prolonged or repeated exposure if swallowed.



Version 5.1	Revision Date: 30.09.2023	SDS Number: 58633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
Preca	autionary statements	· Prevention:	
		P201 Obtain P202 Do not and understo P264 Wash s	kin thoroughly after handling. rotective gloves/ protective clothing/ eye protec-
		Response:	
		for several mi easy to do. C P308 + P313 attention.	 + P338 IF IN EYES: Rinse cautiously with water inutes. Remove contact lenses, if present and ontinue rinsing. IF exposed or concerned: Get medical advice/ If eye irritation persists: Get medical advice/ at-

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 20 -< 30
Lamivudine	134678-17-4	>= 10 -< 20
Tenofovir	202138-50-9	>= 10 -< 20
Doravirine	1338225-97-0	>= 1 -< 10

Section 4: First-aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with plenty of water.



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.1	Revision Date: 30.09.2023	-	0S Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
If swa Most and e delay Prote	ction of first-aiders	: :	Get medical atter Wash clothing be Thoroughly clean In case of contact for at least 15 min If easy to do, rem Get medical atter If swallowed, DO Get medical atter Rinse mouth thor Causes serious e Suspected of dam May cause dama exposure if swalld First Aid respond and use the recor when the potentia	fore reuse. shoes before reuse. t, immediately flush eyes with plenty of water nutes. ove contact lens, if worn. tition. NOT induce vomiting. noughly with water. ye irritation. naging the unborn child. ge to organs through prolonged or repeated owed. ers should pay attention to self-protection, mmended personal protective equipment al for exposure exists (see section 8).
	s to physician : Fire-fighting measure	: s	Treat symptomati	cally and supportively.
	ble extinguishing media	:	Water spray Alcohol-resistant Carbon dioxide (0 Dry chemical	
Unsu media	itable extinguishing a	:	None known.	
	ific hazards during fire-	:	concentrations, a potential dust exp	dust; fine dust dispersed in air in sufficient nd in the presence of an ignition source is a plosion hazard. bustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides Nitrogen oxides (Halogenated com Metal oxides	
Spec ods	ific extinguishing meth-	:	cumstances and Use water spray	g measures that are appropriate to local cir- the surrounding environment. to cool unopened containers. ged containers from fire area if it is safe to d
	ial protective equipment efighters	:	In the event of fire	e, wear self-contained breathing apparatus. tective equipment.

Section 6: Accidental release measures

Personal precautions, protec- :	Use personal protective equipment.
tive equipment and emer-	Follow safe handling advice (see section 7) and personal pro-



Version 5.1	Revision Date: 30.09.2023		Number: 33-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
genc	y procedures	t	ective equipment	recommendations (see section 8).
Envir	onmental precautions	F	Retain and dispos	akage or spillage if safe to do so. se of contaminated wash water. should be advised if significant spillages
	ods and materials for ainment and cleaning up	t V E E L F F F F S	ainer for disposal Avoid dispersal of with compressed Dust deposits sho es, as these may eased into the atr local or national r local of this mate employed in the c nine which regula Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

Section 7: Handling and storage

Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation Advice on safe handling	 Use only with adequate ventilation. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges.
Hygiene measures	 Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment,



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date: 30.09.2023	SDS Number:	Date of last issue: 04.04.2023
5.1		58633-00027	Date of first issue: 16.02.2015
	ions for safe storage als to avoid	industrial hygiend use of administra : Keep in properly Store locked up. Store in accorda	labelled containers. nce with the particular national regulations. the following product types:

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Cellulose	9004-34-6	WES-TWA	10 mg/m3	NZ OEL
		TWA	10 mg/m3	ACGIH
Lamivudine	134678-17-4	TWA	100 µg/m3 (OEB 2)	Internal
Tenofovir	202138-50-9	TWA	150 ug/m3 (OEB 2)	Internal
Doravirine	1338225-97- 0	TWA	500 ug/m3 (OEB2)	Internal

Engineering measures	:	Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
----------------------	---	--

Personal protective equipment

Respiratory protection Filter type Hand protection	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Particulates type
•		
Material	:	Chemical-resistant gloves
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat.
Skin and body protection	:	Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance

: powder



Version 5.1	Revision Date: 30.09.2023		S Number: 33-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
Co	lour	:	No data available	
Od	our	:	No data available)
Od	our Threshold	:	No data available	9
pН		:	No data available)
Me	Iting point/freezing point	:	No data available	9
Init ran	ial boiling point and boiling ge	:	No data available)
Fla	sh point	:	Not applicable	
Eva	aporation rate	:	Not applicable	
Fla	mmability (solid, gas)	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans.
Fla	mmability (liquids)	:	No data available	9
	per explosion limit / Upper nmability limit	:	No data available	9
	ver explosion limit / Lower nmability limit	:	No data available)
Vaj	oour pressure	:	Not applicable	
Re	lative vapour density	:	Not applicable	
Re	lative density	:	No data available)
De	nsity	:	No data available)
	ubility(ies) Water solubility	:	No data available	9
	rtition coefficient: n-	:	Not applicable	
	anol/water to-ignition temperature	:	No data available	2
De	composition temperature	:	No data available	9
Vis	cosity Viscosity, kinematic	:	Not applicable	
	plosive properties	:	Not explosive	



/ersion 5.1	Revision Date: 30.09.2023		S Number: 533-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015	
Oxidiz	zing properties	:	The substance o	r mixture is not classified as oxidizing.	
Molec	cular weight	:	No data available	9	
Partic	Particle size		No data available	9	
Section 10): Stability and reactivi	ty			
	ivity lical stability bility of hazardous reac-		Stable under nor May form explos dling or other me	ive dust-air mixture during processing, han-	
Condi	tions to avoid	:	Heat, flames and		
	patible materials dous decomposition cts	:	Avoid dust formation.Oxidizing agentsNo hazardous decomposition products are known.		
ection 11	1: Toxicological inform	atio	'n		
Expos	sure routes	:	Inhalation Skin contact Ingestion Eye contact		
Acute	e toxicity				
	assified based on availa	ble i	information.		
<u>Produ</u> Acute	<u>uct:</u> oral toxicity	:	Acute toxicity esti Method: Calculati	mate: > 2,000 mg/kg on method	
Comp	oonents:				
Cellu Acute	lose: oral toxicity	:	LD50 (Rat): > 5,0	00 mg/kg	
Acute	inhalation toxicity	:	LC50 (Rat): > 5.8 Exposure time: 4 Test atmosphere:	h	
Acute	dermal toxicity	:	LD50 (Rabbit): > 2	2,000 mg/kg	
	vudine: oral toxicity	:	: LD50 (Rat): > 2,000 mg/kg		



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

sion	Revision Date: 30.09.2023		DS Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
			LD50 (Mouse): 4,	
			Remarks: No mo	rtality observed at this dose.
	toxicity (other routes of histration)	:	LD50 (Rat): > 2,0 Application Route	
Teno	fovir:			
Acute	oral toxicity	:	LD50 (Rat): > 1,5	i00 mg/kg
			LD50 (Dog): 30 n	ng/kg
Dora	virine:			
Acute	oral toxicity	:	LD50 (Rat): > 750 Remarks: No mo	0 mg/kg rtality observed at this dose.
			(Rat): Method: P Remarks: No evic	hototoxicity dence of phototoxicity was observed
			LD50 (Dog): > 1,0 Remarks: No mo	000 mg/kg rtality observed at this dose.
			LD50 (Mouse): > Remarks: No mo	450 mg/kg rtality observed at this dose.
Skin	corrosion/irritation			
	lassified based on availa	ble	information.	
<u>Comp</u>	oonents:			
Lami	vudine:			
Speci		:	Rabbit	
Resul		:	Mild skin irritation	I
_	fovir:			
Teno	es	:	Rabbit	
Speci			Mild skin irritation	1
		·		
Speci Resul		•		

Serious eye damage/eye irritation

Causes serious eye irritation.



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.1	Revision Date: 30.09.2023	SDS Number: 58633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
Com	nononto		
	ponents:		
Lami	vudine:		
Spec		: Rabbit	
Resu	lt	: No eye irritatio	n
Teno	fovir:		
Spec	ies	: Rabbit	
Resu	lt	: Severe irritation	on
Dora	virine:		
Rema	arks	: No data availa	able

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Lamivudine:

Exposure routes	:	Dermal
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

Tenofovir:

Test Type	:	Maximisation Test
Exposure routes	:	Skin contact
Species	:	Guinea pig
Result	:	Not a skin sensitizer.

Doravirine:

Remarks

: No data available

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

1

Components:

Cellulose:

Genotoxicity in vitro

Test Type: Bacterial reverse mutation assay (AMES) Result: negative



Genoto Lamivu	kicity in vivo	:	Test Type: In Result: negati	vitro mammalian cell gene mutation test	
	kicity in vivo	:			
	kicity in vivo			Ve	
Lamivu	Genotoxicity in vivo		: Test Type: Mammalian erythrocyte micronucleus cytogenetic assay) Species: Mouse Application Route: Ingestion Result: negative		
	dine:				
Genoto	kicity in vitro		Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve	
			Test Type: Mo Result: equivo	ouse Lymphoma Ical	
Genoto	Genotoxicity in vivo		Test Type: Mid Species: Rat Application Ro Result: negati		
				scheduled DNA synthesis (UDS) test with ver cells in vivo ve	
Tenofo	vir:				
	kicity in vitro		Test Type: Ba Result: equivo	cterial reverse mutation assay (AMES) cal	
			Test Type: In Result: positiv	vitro mammalian cell gene mutation test e	
Genoto	kicity in vivo		cytogenetic te Species: Mous	oute: Intraperitoneal injection	
Germ ce Assessr	ell mutagenicity - nent		Weight of evid cell mutagen.	lence does not support classification as a germ	
Doravir	ine:				
	kicity in vitro		Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve	
				romosomal aberration Chinese hamster ovary cells	



Version 5.1	Revision Date: 30.09.2023	SDS Number: 58633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
		Result: negat	ive
Geno	toxicity in vivo	: Test Type: M Species: Rat Cell type: Bo Application R Result: negat	oute: Oral
	nogenicity assified based on ava	ailable information.	
Com	oonents:		
Cellu	lose:		
	cation Route sure time	: Rat : Ingestion : 72 weeks : negative	
Lami	vudine:		
Speci Expos Resul	sure time	: Rat : 2 Years : negative	
Speci Expos Resul	sure time	: Mouse : 2 Years : negative	
Teno	fovir:		
	cation Route sure time	: Mouse : Oral : 104 weeks : negative	
	cation Route sure time	: Rat : Oral : 104 weeks : negative	
Dora	virine:		
	cation Route sure time It	: Mouse : Oral : 6 Months : negative : No significan	t adverse effects were reported

Reproductive toxicity

Suspected of damaging the unborn child.



Version 5.1			DS Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
Con	<u>iponents:</u>			
Cell	ulose:			
	cts on fertility	:	Test Type: One- Species: Rat Application Rout Result: negative	
	Effects on foetal develop- ment		Test Type: Fertil Species: Rat Application Rout Result: negative	
Lam	ivudine:			
Effe	cts on fertility	:	Species: Rat Application Rout Fertility: NOAEL	: 900 mg/kg body weight ts on fertility and early embryonic develop-
Effe men	cts on foetal develop- t	:	Species: Rabbit Application Rout Symptoms: Prei	mplantation loss, Skeletal malformations oxic effects and adverse effects on the off-
			Species: Rat Application Rout Developmental	ryo-foetal development te: Oral Foxicity: LOAEL: 45 mg/kg body weight cts on foetal development
•	roductive toxicity - As-	:	Some evidence animal experime	of adverse effects on development, based on ents.
Ten	ofovir:			
	cts on fertility	:	Test Type: Fertil Species: Rat Application Rout Result: No effec	
Effermen	cts on foetal develop- t	:	Test Type: Emb Species: Rat Application Rout Result: No adve	



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

ersion 1	Revision Date: 30.09.2023	SDS Number: 58633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
		Test Type: Em Species: Rabb Result: No adv	
Dora	virine:		
Effect	s on fertility	•	nale and female :L: 450 mg/kg body weight
Effect ment	s on foetal develop-	Species: Rat Application Ro	I Toxicity: NOAEL: 450 mg/kg body weight
		Species: Rabb Application Ro	ute: Oral I Toxicity: NOAEL: 300 mg/kg body weight

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Blood, Bone, Kidney) through prolonged or repeated exposure if swallowed.

Components:

Lamivudine: Exposure routes Target Organs Assessment	 Ingestion Blood May cause damage to organs through prolonged or repeated exposure.
Tenofovir: Target Organs Assessment	 Bone, Kidney May cause damage to organs through prolonged or repeated exposure.
Repeated dose toxicity	
Components:	
Cellulose:	

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg



Version 5.1	Revision Date: 30.09.2023	SDS Number: 58633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
	cation Route sure time	: Ingestion : 90 Days	
	vudine:	· Pot	
Expos	EL cation Route sure time et Organs toms		al discomfort, Breathing difficulties, Fatality kicity observed in testing
Expos	L cation Route sure time tt Organs		, Liver arrhoea, Changes in the blood count, Liver dis- pintestinal disturbance
Expos		: Mouse : 500 mg/kg : Oral : 1 Months : Blood	
Expos	es EL	: Rat : 30 mg/kg : 300 mg/kg : Oral : 13 Weeks : Bone	
Expos	EL	: Dog : 3 mg/kg : >= 10 mg/kg : Oral : 42 Weeks : Kidney	
Expos		: Monkey : 10 mg/kg : Subcutaneous : 10 Months : Bone	S
	virine:	. D-4	
Speci	es	: Rat	



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version 5.1	Revision Date: 30.09.2023		DS Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
NOA		:	450 mg/kg	
	cation Route	:	Oral	
	sure time	:	6 Months	
Rema	arks	:	No significant a	adverse effects were reported
Spec	ies	:	Mouse	
NOA		:	> 450 mg/kg	
	cation Route	:	Oral	
	sure time	:	3 Months	
Rema	arks	:	No significant a	adverse effects were reported
Spec	ies	:	Dog	
NOA	EL	:	> 1,000 mg/kg	
Appli	cation Route	:	Oral	
Expo	sure time	:	9 Months	
Rema	arks	:	No significant a	adverse effects were reported
Aspi	ration toxicity			
•	lassified based on av	ailable	information.	
Expe	rience with human e	isoux	Ire	

Experience with human exposure

Components:

Lamivudine:	
Ingestion	Symptoms: Headache, Fatigue, Respiratory disorders, Diar- rhoea, Cough
Tenofovir:	
Ingestion :	Symptoms: Nausea, Diarrhoea, Vomiting, flatulence, Head- ache, Rash
Doravirine:	
Ingestion :	Symptoms: confusion, Headache, Dizziness, Nausea, Rash, abnormal dreams, flushing, Neurological disorders, mental depression

Section 12: Ecological information

Ecotoxicity		
Components:		
Cellulose: Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
Lamivudine: Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 97.7 mg/l



ersion .1	Revision Date: 30.09.2023		9S Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
			Exposure time: 96 Method: OECD Te	
	to daphnia and other invertebrates	:	EC50 (Daphnia m Exposure time: 48 Method: OECD Te	
Toxicity plants	to algae/aquatic	:	EC50 (Pseudokiro mg/l Exposure time: 72 Method: OECD Te	
			NOEC (Pseudokir mg/l Exposure time: 72 Method: OECD Te	
Tenofo	vir:			
Toxicity plants	v to algae/aquatic	:	EC50 (Raphidoce mg/l End point: Growth Exposure time: 72 Method: OECD Te	2 h
			NOEC (Raphidoco mg/l Exposure time: 72 Method: OECD Te	
Toxicity icity)	to fish (Chronic tox-	:	NOEC (Pimephale Exposure time: 32 Method: OECD Te	
	to daphnia and other invertebrates (Chron- ty)	:	NOEC (Daphnia r Exposure time: 21 Method: OECD Te	
Toxicity	to microorganisms	:	EC50: > 1,000 mg Exposure time: 3 Test Type: Respir Method: OECD Te	h ration inhibition
			NOEC: > 1,000 m Exposure time: 3 Test Type: Respir Method: OECD Te	h ation inhibition
Doravii	rine:			
		:	EC50 (Daphnia m	agna (Water flea)): > 39 mg/l



/ersion 5.1	Revision Date: 30.09.2023		9S Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
aqu	atic invertebrates			8 h Fest Guideline 202 icity at the limit of solubility
			EC50 (Americam Exposure time: 9	
Tox plar	icity to algae/aquatic hts	:	mg/l Exposure time: 7 Method: OECD 1	rchneriella subcapitata (green algae)): > 5 '2 h Fest Guideline 201 icity at the limit of solubility
			mg/l Exposure time: 7 Method: OECD 1	irchneriella subcapitata (green algae)): 5.8 2 h Fest Guideline 201 icity at the limit of solubility
Tox icity	icity to fish (Chronic tox- /)	:	Exposure time: 3 Method: OECD 1	les promelas (fathead minnow)): 1 mg/l 2 d Fest Guideline 210 icity at the limit of solubility
aqu	icity to daphnia and other atic invertebrates (Chron- oxicity)	:	Exposure time: 2 Method: OECD 1	magna (Water flea)): 6.7 mg/l 1 d Fest Guideline 211 icity at the limit of solubility
Тох	icity to microorganisms	:	EC50: > 1,000 m Exposure time: 3 Test Type: Resp Method: OECD 1	5 ĥ
			NOEC: 1,000 mg Exposure time: 3 Test Type: Resp Method: OECD 1	h
Per	sistence and degradabili	ty		
<u>Cor</u>	nponents:			
Cel	lulose:			
Bio	degradability	:	Result: Readily b	iodegradable.
	nivudine: degradability	:	Result: Not readi Biodegradation: Exposure time: 2	
			17 / 21	



ersion .1	Revision Date: 30.09.2023		DS Number: 633-00027	Date of last issue: 04.04.2023 Date of first issue: 16.02.2015
Teno	fovir:			
Biode	gradability	:	Biodegradation: 3 Exposure time: 28	3.66 %
Dorav	virine:			
Biode	gradability	:	Result: Not readil Biodegradation: 2 Exposure time: 28	2 %
Bioad	cumulative potential			
<u>Comp</u>	oonents:			
Partiti	vudine: on coefficient: n- ol/water	:	log Pow: -1.44	
Teno				
Partiti	on coefficient: n- ol/water	:	log Pow: 1.06 pH: 7	
Partiti	/irine: on coefficient: n- ol/water	:	log Pow: 2.08	
Mobil	ity in soil			
<u>Comp</u>	oonents:			
Distrib	vudine: oution among environ- al compartments	:	log Koc: 2.03	
	fovir: oution among environ- al compartments	:	log Koc: 3.33 Method: OECD T	est Guideline 106
Dora	virine:			
	oution among environ- al compartments	:	log Koc: 2.86	
	adverse effects ata available			



Version	Revision Date:	SDS Number:	Date of last is
5.1	30.09.2023	58633-00027	Date of first is

Date of last issue: 04.04.2023 Date of first issue: 16.02.2015

Section 13: Disposal considerations

Disposal methods		
Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han-
		dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number Proper shipping name Class Subsidiary risk Packing group Labels		Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
IATA-DGR UN/ID No. Proper shipping name Class Subsidiary risk Packing group Labels Packing instruction (cargo aircraft) Packing instruction (passen- ger aircraft)		Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
IMDG-Code UN number Proper shipping name Class	:	Not applicable Not applicable Not applicable

Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

UN number	: 1	Not applicable
Proper shipping name	: 1	Not applicable
Class	: 1	Not applicable



Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate Bilayer Formulation

Version	Revision Date: 30.09.2023	SDS Number:	Date of last issue: 04.04.2023
5.1		58633-00027	Date of first issue: 16.02.2015

Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100425 Pharmaceutical Active Ingredients Group Standard

HSW Controls

Certified handler certificate not required. Tracking hazardous substance not required. Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

Section 16: Other information

Revision Date	:	30.09.2023	
Further information			
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/	
Date format	:	dd.mm.yyyy	
Full text of other abbreviations			
ACGIH NZ OEL	:	USA. ACGIH Threshold Limit Values (TLV) New Zealand. Workplace Exposure Standards for Atmospher- ic Contaminants	
ACGIH / TWA NZ OEL / WES-TWA	:	8-hour, time-weighted average Workplace Exposure Standard - Time Weighted average	

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -



Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	58633-00027	Date of first issue: 16.02.2015

Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN